Jennifer M. Yeh, PhD; Zachary J. Ward, MPH; Aeysha Chaudhry, MSc; et al.
free access
JAMA Oncol. 2020;6(3):350-357. doi:10.1001/jamaoncol.2019.5582
This decision analytical model–based study uses data from the Childhood Cancer Survivor Study to project long-term survival and assess whether life expectancy will improve among adult survivors of childhood cancer who were treated in more recent decades.
-
Editorial
Minding the Gap for Survivors of Childhood Cancer
Stephanie M. Smith, MD, MPH; Michael P. Link, MD; Karen E. Effinger, MD, MS
JAMA Oncol
Shuhong Shen, MD, PhD; Xiaojuan Chen, MD, PhD; Jiaoyang Cai, MD, PhD; et al.
free access
JAMA Oncol. 2020;6(3):358-366. doi:10.1001/jamaoncol.2019.5868
This phase 3 randomized clinical trial assesses whether dasatinib given at 80 mg/m2 is more effective than imatinib mesylate at 300 mg/m2 to improve event-free survival in children with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Joseph A. Sparano, MD; Robert J. Gray, PhD; Della F. Makower, MD; et al.
free access
JAMA Oncol. 2020;6(3):367-374. doi:10.1001/jamaoncol.2019.4794
This secondary anaysis of the TAILORx randomized clinical trial describes clinical outcomes for women with a high 21-gene recurrence score who received adjuvant chemotherapy plus endocrine therapy, a population expected to have a high distant recurrence rate with endocrine therapy alone.
Jianchun Duan, MD; Longgang Cui, PhD; Xiaochen Zhao, MD; et al.
free access
JAMA Oncol. 2020;6(3):375-384. doi:10.1001/jamaoncol.2019.5367
This systematic review and meta-analysis of randomized clinical trials examines use of programmed cell death 1 (PD-1) vs programmed cell death–ligand 1 (PD-L1) treatment in patients with cancer.
Naomi Y. Ko, MD, MPH, AM; Susan Hong, MD, MPH; Robert A. Winn, MD; et al.
free access
JAMA Oncol. 2020;6(3):385-392. doi:10.1001/jamaoncol.2019.5672
This cross-sectional study uses data from the Surveillance, Epidemiology, and End Results Program to examine the extent to which insurance is associated with access to timely breast cancer diagnosis and breast cancer stage differences among a large, diverse population of US patients with breast cancer.
Jill Furzer, MA; Sumit Gupta, MD, PhD; Paul C. Nathan, MD, MSc; et al.
free access
JAMA Oncol. 2020;6(3):393-401. doi:10.1001/jamaoncol.2019.5909
This cost-utility analysis assesses the value of tisagenlecleucel compared with current standard care for tisagenlecleucel-eligible pediatric patients with acute lymphoblastic leukemia.
Ciara M. Kelly, MBBCh, BAO, MD; Cristina R. Antonescu, MD; Timothy Bowler, MD; et al.
free access
JAMA Oncol. 2020;6(3):402-408. doi:10.1001/jamaoncol.2019.6152
This phase 2 clinical trial examines whether talimogene laherparepvec in combination with pembrolizumab is associated with increased tumor-infiltrating lymphocyte infiltration and programmed death-ligand 1 expression, and thus with increased antitumor activity in patients with locally advanced or metastatic sarcoma.
Mohamad Bassam Sonbol, MD; Luke J. Mountjoy, DO; Belal Firwana, MD; et al.
free access
online only
has audio
JAMA Oncol. 2020;6(3):e194489. doi:10.1001/jamaoncol.2019.4489
This systematic review and network meta-analysis of randomized clinical trials evaluates the comparative effectiveness of different treatment strategies in metastatic colorectal cancer.
-
Podcast:
The Role of Maintenance Strategies in Metastatic Colorectal Cancer